(38) identified methyltransferase 3 (METTL3) as a key negative regulator, loss of Mettl3 accelerates NASH by enhancing CD36-dependent fatty acid uptake and CCL2-driven inflammation. Here, CCL2 is linked to metabolic dysfunction-associated steatohepatitis.